While research in mice has shown encouraging results, the next phases of human trials will need to confirm safety and ...

Daratumumab effectively delays multiple myeloma relapse by monitoring minimal residual disease, offering hope for improved ...

Scientists at St. Jude Children's Research Hospital and Dana-Farber Cancer Institute today report the identification of a ...

Hyundai Hope on Wheels contributes $250,000 to support the art therapy program at the Charles-Bruneau Foundation for children ...

In this video, Megan Kruse, MD, breast medical oncologist at Cleveland Clinic, discusses primary results from ASCENT-04 evaluating sacituzumab govitecan plus pembrolizumab in metastatic ...

In CAR T-cell therapy for diffuse large B-cell lymphoma, distinct archetypes could guide personalized treatment decisions.

Combination therapy with savolitinib and osimertinib shows promising results in treating advanced NSCLC with EGFR mutations ...

Trials enrolling patients with relapsed leukemia, lymphoma and brain cancers, respectively, report early data showing ...

The trial of a new drug, bexobrutideg, shows promising results for chronic lymphocytic leukemia patients previously treated ...

Pharma/biotech giants Pfizer PFE and Bristol Myers BMY boast of a dominant position in the lucrative oncology space. Oncology ...

Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company ...

Researchers sought to determine whether a reduced dose of apixaban would be as effective as using full-dose apixaban in preventing recurrent VTE in patients with active cancer.